Luxdegalutamide (ARV-766) is an orally active PROTAC that targets the androgen receptor (AR) for degradation, including resistant mutants such as T878, H875, and L702. Its structural design facilitates the study of mechanisms related to castration-resistant prostate cancer.
Usually ships within 24 hours.